The Benefits of NURTEC ODT

NURTEC™ ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in orally disintegrating tablet (ODT) for the acute treatment of migraine in adults. It is not indicated for the preventive treatment of migraine. NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components.

Trains a root cause of migraine in a unique, slow, and rapid and sustained manner

Ease of use with orally disintegrating tablet

Fast relief and return to normal function at least twice in many patients

The most common adverse reactions were (2% of patients) nausea. This is not the only possible adverse effect of NURTEC ODT. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects.

Select Important Safety Information

Hypersensitivity reactions, including immediate and delayed reactions, have occurred with NURTEC ODT in clinical studies. Hypersensitivity reactions with delayed hypersensitivity may develop after administration, occurring in less than 1% of patients taking NURTEC ODT in clinical studies.

Cardiovascular System

NURTEC ODT may offer an alternative treatment option, particularly for patients who experience contraindication to currently available therapies.

NURTEC ODT orally disintegrating tablets is a prescription medicine for the acute treatment of migraine for attacks with or without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in orally disintegrating tablet (ODT) for the acute treatment of migraine in adults. It is not indicated for the preventive treatment of migraine. NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components.

NURTEC™ ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in orally disintegrating tablet (ODT) for the acute treatment of migraine in adults. It is not indicated for the preventive treatment of migraine. NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components.

The most common adverse reaction was nausea (2% of patients). This is not the only possible adverse effect of NURTEC ODT. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects.

Select Important Safety Information

Hypersensitivity reactions, including immediate and delayed reactions, have occurred with NURTEC ODT in clinical studies. Hypersensitivity reactions with delayed hypersensitivity may develop after administration, occurring in less than 1% of patients taking NURTEC ODT in clinical studies.

Cardiovascular System

NURTEC ODT may offer an alternative treatment option, particularly for patients who experience contraindication to currently available therapies.

NURTEC ODT orally disintegrating tablets is a prescription medicine for the acute treatment of migraine for attacks with or without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in orally disintegrating tablet (ODT) for the acute treatment of migraine in adults. It is not indicated for the preventive treatment of migraine. NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components.

NURTEC™ ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in orally disintegrating tablet (ODT) for the acute treatment of migraine in adults. It is not indicated for the preventive treatment of migraine. NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components.

The most common adverse reaction was nausea (2% of patients). This is not the only possible adverse effect of NURTEC ODT. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or report side effects.